- About 80% of breast tumours are ductal carcinoma; 10–15% are lobular; inflammatory breast cancer is rarer and more aggressive.
- The classic symptom is a hard, painless lump — breast pain is NOT a typical sign.
- Caught local (stage 0–I), five-year survival exceeds 99%; distant (stage IV) drops to ~31% — early detection is decisive.
- Genetics accounts for only ~5–10% of cases (BRCA1/BRCA2); estrogen excess and lifestyle drive the majority.
Breast cancer classification
Almost 80% of breast tumours are ductal carcinoma. In 10–15% of cases lobular carcinoma is found. There is also inflammatory breast cancer, which behaves differently biologically — marked by pronounced reddening of the skin and breast, swelling and pain, and fairly early metastasis to the lymph nodes.
Breast cancer symptoms
The main symptom of breast cancer is a hard, painless lump felt in the breast. Other signs include a change in breast shape; a retracted, inverted or altered nipple; enlarged armpit lymph nodes; and nipple discharge — especially if it is bloody and comes from only one breast. Breast pain is not a typical cancer symptom.
Treatment of metastatic (spread) cancer depends on where the metastases are. Metastases in the lungs and pleura cause cough, shortness of breath and progressive respiratory failure. Liver metastases cause no symptoms at first, then pain and progressive liver failure. Skeletal metastases cause pain in the affected bones. Brain metastases cause headaches, nausea, vomiting and neurological symptoms.
Breast cancer stages (TNM)
| Stage | TNM |
|---|---|
| Stage 0 | Tis N0 M0 |
| Stage 1 | T1 N0 M0 |
| Stage 2A | T0, T1/T2 · N1/N0 · M0 |
| Stage 2B | T2/T3 · N1/N0 · M0 |
| Stage 3A | T0–T3 · N1, N2 · M0 |
| Stage 3B | T4 · N0, N1, N2 · M0 |
| Stage 3C | any T · N3 · M0 |
| Stage 4 | any T · any N · M1 |
Breast cancer treatment
Breast cancer is treated not with a single method, but with a combination. The foundation is surgery (removal). Also used are chemotherapy, radiotherapy, hormonal treatment and targeted therapy. Treatment depends on the spread, stage and prognosis. Patients are sorted into risk groups to assess how aggressively the disease is progressing and to choose the treatment approach.
Breast cancer survival
| Spread | Stage | 5-year survival |
|---|---|---|
| Local | Stage 0 and I, part of II | >99% |
| Regional | Rest of II and III | ~86% (average) |
| Distant | Stage IV | ~31% |
Data from the National Cancer Institute SEER database — the general statistic for the percentage of patients surviving 5 years after a breast cancer diagnosis.
The causes of breast cancer
Many people still regard cancer as a terrible "lottery" or a blow of genetic fate. But the numbers say otherwise. Although cancer is an old disease, a century ago fewer than 3% of the population had it; today the diagnosis catches up with one in two or three people.1 Why? The modern preventive system (mammograms, screening) is an excellent safety net that helps catch the disease early and reach 99% survival — but screening does not prevent the disease itself. It is like checking your car tyres daily for punctures while continuing to drive over nails. The prevention system jams, and will keep jamming, until people themselves grasp that they alone are responsible for being healthy — not their doctor, the government, or the companies that make and sell drugs.
What are estrogens?
Estrogens are the female sex hormones. They influence pregnancy, conception, libido, the formation of the mammary glands, help regulate menstrual cycles and are needed for normal breast development. Although estrogens are essential to a woman's health (from bone strength to heart protection), an excess or the wrong form of them is a direct route to breast cancer. The problem arises when the body receives too many "foreign" estrogens or fails to clear its own.
Things that raise estrogen levels include: contraceptives — modern low-dose pills raise risk only minimally, but long-term use (over many years) is still linked to a slightly increased breast cancer risk;7 the good news is that after stopping, this risk returns to baseline within a few years. Hormone replacement therapy (HRT) — therapy given to post-menopausal women (especially combined forms) also raises risk.
What to do to recover
Breast cancer survival prognoses are, statistically, not very grim — especially in early stages. This is exactly why preventive testing and regular self-examination matter so much. But if you were late with prevention, do not despair and do not give up: the likelihood of successful treatment depends in large part on you too.
Cancer cells can send a "do not attack me" signal, so your defences (immune cells) often do not see them. You need natural immunomodulators — such as Lentinan — to change how the immune system behaves and direct it to attack cancer cells with maximum force. In fighting cancer you must adapt your diet (feast yourself while starving the cancer) and activate the immune system.
Cancer cells send 'do not attack me' signals. Concentrated mushroom polysaccharides are studied for their role in supporting NK-cell and macrophage activity alongside treatment.
Lentinan AXT by Zenius Labs™ →The most common signs are a palpable lump in the breast (painful or not), skin changes (retraction, redness), nipple discharge, or a change in nipple shape. However, in the early stages cancer often causes no symptoms at all, which is why regular preventive screening (mammography) is so important.
Yes. Supporting the immune system during treatment is very important, especially during chemotherapy when the body is weakened. Research shows that certain mushroom-polysaccharide extracts may help activate natural killer (NK) cells and macrophages. Specialists recommend choosing concentrated multi-extract formulas, for example Lentinan AXT by Zenius Labs™.
Genetics accounts for only about 5–10% of all breast cancer cases (most often BRCA1 and BRCA2 gene mutations). The great majority of cases are linked to lifestyle and environmental factors, so there is much you can influence.
For breast cancer diagnosed early (stage I), five-year survival exceeds 90%. But even after successful treatment the risk of recurrence remains, so long-term strengthening of the body and immune-system support with concentrated mushroom-polysaccharide formulas stays important.
The most important factors are a balanced diet, regular physical activity, maintaining a normal body weight, limiting alcohol and managing stress. Regular health checks and caring for a strong immune system are also recommended.
- Red meat consumption and breast cancer risk. Harvard T.H. Chan
- Overdiagnosis of breast cancer after 14 years of mammography screening. PubMed
- Breast cancer risk and endogenous estrogens. ScienceDirect
- State of the evidence 2017: connection between breast cancer and the environment. PubMed
- Alcohol Use and Cancer. cancer.org
- Liu Z et al. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer. Frontiers in immunology. 2023. PubMed
- Desroys du Roure P et al. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer. 2024. PubMed
- Han E et al. Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer. Breast cancer research : BCR. 2024. PubMed
- Ding S et al. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer. Cancer communications (London, England). 2023. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Luo L et al. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular cancer. 2025. PubMed
- Zheng G et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal transduction and targeted therapy. 2021. PubMed
- Collins DM et al. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021. PubMed
- Blackburn AM et al. Tamoxifen and liver damage. British medical journal (Clinical research ed.). 1984. PubMed
- Zhou WB et al. Osthole prevents tamoxifen-induced liver injury in mice. Acta pharmacologica Sinica. 2019. PubMed
- Tabassum H et al. Catechin as an antioxidant in liver mitochondrial toxicity: Inhibition of tamoxifen-induced protein oxidation and lipid peroxidation. Journal of biochemical and molecular toxicology. 2007. PubMed
- Elefsiniotis IS et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. European journal of gastroenterology & hepatology. 2004. PubMed
- Li Y et al. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer. Frontiers in cell and developmental biology. 2021. PubMed
- Hermsen BB et al. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. European journal of cancer (Oxford, England : 1990). 2007. PubMed
- Muñante B et al. Clinical Management in BRCA Carriers with Early Breast Cancer. Cancer control : journal of the Moffitt Cancer Center. 2025. PubMed
- Grandal B et al. Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers. 2020. PubMed
- Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
- Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
- Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
- Hermans L et al. β-Glucan-Induced IL-10 Secretion by Monocytes Triggers Porcine NK Cell Cytotoxicity. Frontiers in immunology. 2021. PubMed
- Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
- Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
- Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
- Yoshinaga K et al. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). Fukuoka igaku zasshi = Hukuoka acta medica. 2013. PubMed
- Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
- Genç Y et al. Oxidative Stress and Marine Carotenoids: Application by Using Nanoformulations. Marine drugs. 2020. PubMed
- Ávila-Román J et al. Anti-Inflammatory and Anticancer Effects of Microalgal Carotenoids. Marine drugs. 2021. PubMed
- Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
- Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
- Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine. 2014. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
- Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
- Zhang M et al. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Progress in molecular biology and translational science. 2019. PubMed
- Larnder AH et al. The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer. International journal of cancer. 2025. PubMed
- Kwa M et al. The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. Journal of the National Cancer Institute. 2016. PubMed
- Huang Y et al. Intratumoral Microbiome-related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy. Radiology. 2025. PubMed
- Zetner D et al. Effect of melatonin cream on acute radiation dermatitis in patients with primary breast cancer: A double-blind, randomized, placebo-controlled trial. Journal of pineal research. 2023. PubMed
- Zetner D et al. Quality-of-life outcomes following topical melatonin application against acute radiation dermatitis in patients with early breast cancer: A double-blind, randomized, placebo-controlled trial. Journal of pineal research. 2023. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed